Eli Lilly and Company

The transcript does not mention any current or future fundraising activities through debt or equity. Key points related to financial activities include: - Updated revenue guidance for the full year with increased investment in supply and demand creation. - Investment in ramping up supply capacity and demand generation activities through 2024 and into 2025. - No specific discussion or indication of new debt issuance or equity fundraising plans. - CFO Lucas Montarce discusses operating margins and investments in SG&A and R&D but does not mention external financing. - Other income and expense guidance is provided without reference to financing transactions. In summary, there is no disclosed plan or indication of raising funds through debt or equity in the discussed quarters or near future.

- Lilly is scaling R&D and stepping up investments across manufacturing and commercial to support successful launches of new medicines (Page 3). - There has been massive investment in parenteral filling capacity and API capacity; delivery schedules take 2-4 years to impact supply (Page 4). - New capacity efforts are accelerating supply growth, with significant supply capacity expansions announced over the last few years coming online soon, supporting strong growth expected in 2025 (Page 5). - Demand generation activities in SG&A will ramp up in 2025, reflecting continued investments to drive commercial success (Page 8). - Investments are balanced with expanding operating margins in the short term, while ensuring sustainable growth for future returns (Page 8).

- Lilly expects strong revenue growth driven primarily by new products Mounjaro and Zepbound, with U.S. sequential quarter-over-quarter prescriptions continuing to grow. - They anticipate 50% growth for the fourth quarter of 2024, with steady acceleration in prescription volumes. - Demand generation efforts will be ramped up significantly starting mid-November 2024 to capitalize on improved supply capacity. - Supply capacity has been increased substantially, targeting at least 1.5 times saleable doses in H2 2024 versus H2 2023, with further expansion planned into 2025. - International launches, including Europe and other countries, will contribute to volume growth. - Operating margin expansion is expected short term, with sustained long-term margin growth supported by investments in SG&A and R&D. - Channel inventory normalization creates some Q3 sales volatility but is expected to stabilize. - Overall, Lilly is confident in robust volume and revenue growth continuing through 2024 and into 2025.

- The company expects continued strong revenue growth, driven notably by new products like Mounjaro and Zepbound. - Operating margin expansion is anticipated in the short term due to ramped-up investments in SG&A and R&D, supporting product launches. - Long-term targets include sustainable operating margin growth that justifies ongoing investments in demand generation and pipeline development. - EPS showed a significant increase in Q3 2024 ($1.19 vs. $0.10 in Q3 2023), including negative impacts from acquired IPR&D charges. - The CFO highlighted an expected operating margin expansion through 2024 and into 2025, balanced with investments to drive demand. - The company aims for high 40s percent operating margins long term but may not explicitly target that level under current leadership. - Demand generation investments will continue, anticipating payoffs in prescription acceleration and sustained profitability growth.

The provided pages from the Eli Lilly earnings call transcript do not explicitly mention current or expected orderbook figures or pending orders in quantitative terms. However, relevant insights include: - Strong revenue growth across key products like Mounjaro and Zepbound, with over 25% sequential growth in prescriptions (TRx). - Supply has improved significantly, with supply-related customer service calls dropping to under 1%, indicating better fulfillment. - Demand is robust, supported by expanding access in commercial, Medicare, and Medicaid markets. - The company expects continued strong growth and supply ramp-up into 2025, aiming for over 50% growth in Q4 and sustained acceleration. - New manufacturing capacity is coming online progressively, supporting increased demand. - Demand generation and commercial investments are ramping up to capture market opportunity without current supply constraints. No specific orderbook or pending order values are disclosed in the transcript excerpts.